New York, New York (PRWEB) August 29, 2013
As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) involving allegations that the drug caused serious, life-threatening episodes of internal bleeding continue to move forward, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has accepted a marketing application to expand the approved uses for the blood thinner. According to a report from Bloomberg Businessweek, Boehringer Ingelheim is seeking to have Pradaxa approved as a treatment for two potentially fatal types of blood clots, deep vein thrombosis and pulmonary embolism.*
“Hundreds of Pradaxa lawsuits have already been filed by plaintiffs who claim to have suffered frightening episodes of internal bleeding while taking this blood thinner, and our Firm continues to regularly receive inquiries from alleged victims of Pradaxa side effects. Unlike some alternative blood thinner treatments, there is no readily available antidote for bleeding that may occur with Pradaxa,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.
According to court documents, more than 1,440 Pradaxa lawsuits have been filed in a multidistrict litigation underway in U.S. District Court, Southern District of Illinois, on behalf of alleged victims of Pradaxa bleeding. All of these claims accuse Boehringer Ingelheim of failing to provide adequate warnings regarding Pradaxa side effects, particularly the lack of an antidote for internal bleeding. The first trials in the Pradaxa bleeding litigation are scheduled to begin in the fall of 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
Pradaxa received FDA approval in October 2010 as a treatment for patients with atrial fibrillation. However, according to a Bloomberg.com report published this past December, regulators in the U.S. and overseas have issued a number of Pradaxa alerts regarding its association with serious internal bleeding, especially the present lack of an antidote for this occurrence. While Pradaxa was touted as an improvement over warfarin, the hemorrhaging that sometimes occurs with this decades- old blood thinner can be staunched with the administration of vitamin K.** In January , a study published by the Institute for Safe Medicine Practices reported that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.
Alleged victims of Pradaxa may be entitled to compensation for their medical bills, lost wages, pain and suffering and more. Read More about Pradaxa bleeding at Bernstein Liebhard LLP’s website. To arrange for a free legal consultation, please call 800-511-5092.
**bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html, Bloomberg.com, December 11, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11076315.htm.
Copyright©2012 Vocus, Inc.
All rights reserved